Uncategorized
FDA sets Sept. 8 for decision on Zerviate NDA
The FDA has set a PDUFA date of Sept. 8 for its decision on the new drug application for Zerviate, according to a Nicox press release.Zerviate (cetirizine ophthalmic solution 0.24%) is an eye drop formulation designed to treat ocular itching associated with allergic conjunctivitis.